NeoPharm has been growing earnings at an average annual rate of 9.7%, while the Personal Products industry saw earnings growing at 21.3% annually. Revenues have been growing at an average rate of 10.1% per year. NeoPharm's return on equity is 14.2%, and it has net margins of 21%.
How NeoPharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A092730 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
132,184
27,823
52,602
3,335
30 Sep 25
129,814
27,797
52,587
3,472
30 Jun 25
123,768
25,274
49,663
3,481
31 Mar 25
122,407
24,090
46,729
3,416
31 Dec 24
119,014
23,065
44,259
3,407
30 Sep 24
112,200
22,334
38,369
3,035
30 Jun 24
107,858
22,929
37,490
2,838
31 Mar 24
101,735
22,516
37,305
2,690
31 Dec 23
97,105
23,213
36,276
2,647
30 Sep 23
92,271
20,733
34,924
2,777
30 Jun 23
89,292
19,781
34,142
2,739
31 Mar 23
86,272
18,912
33,087
2,805
31 Dec 22
85,033
17,027
32,984
2,854
30 Sep 22
86,805
18,245
34,685
2,898
30 Jun 22
87,424
17,370
35,790
3,043
31 Mar 22
87,321
16,905
35,587
2,945
31 Dec 21
87,931
17,713
36,022
2,935
30 Sep 21
86,802
18,207
35,087
2,764
30 Jun 21
85,275
18,059
34,107
2,658
31 Mar 21
85,287
18,474
34,509
2,880
31 Dec 20
81,625
18,131
32,991
2,802
30 Sep 20
81,413
18,734
34,094
2,824
30 Jun 20
82,618
19,935
33,905
2,768
31 Mar 20
82,680
19,901
33,407
2,602
31 Dec 19
83,240
19,245
33,958
2,518
30 Sep 19
79,611
18,002
31,038
2,550
30 Jun 19
74,863
16,675
29,562
2,659
31 Mar 19
69,500
15,795
27,654
2,616
31 Dec 18
66,275
15,370
26,275
2,576
30 Sep 18
63,143
13,682
26,592
2,616
30 Jun 18
60,236
13,105
25,495
2,355
31 Mar 18
57,175
12,514
24,577
2,257
31 Dec 17
53,634
11,559
23,626
2,098
30 Sep 17
49,765
9,814
23,097
2,105
30 Jun 17
46,739
9,365
21,372
2,068
31 Mar 17
43,164
8,096
19,726
2,184
31 Dec 16
42,369
7,742
19,678
2,183
30 Sep 16
43,097
5,955
19,902
2,206
30 Jun 16
41,999
5,419
19,831
2,209
31 Dec 15
35,965
3,407
17,998
1,973
Quality Earnings: A092730 has high quality earnings.
Growing Profit Margin: A092730's current net profit margins (21%) are higher than last year (19.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A092730's earnings have grown by 9.7% per year over the past 5 years.
Accelerating Growth: A092730's earnings growth over the past year (20.6%) exceeds its 5-year average (9.7% per year).
Earnings vs Industry: A092730 earnings growth over the past year (20.6%) did not outperform the Personal Products industry 20.6%.
Return on Equity
High ROE: A092730's Return on Equity (14.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/21 04:45
End of Day Share Price
2026/08/21 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NeoPharm CO., LTD. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.